Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Boehringer Ingelheim
Colorcon
AstraZeneca
Johnson and Johnson

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR ERDAFITINIB


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Erdafitinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02365597 ↗ An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer Recruiting Janssen Research & Development, LLC Phase 2 2015-04-22 The purpose of this study is to evaluate the objective response rate (complete response [CR]+ partial response [PR]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.
NCT02421185 ↗ Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma Completed Janssen Research & Development, LLC Phase 1/Phase 2 2015-05-25 The purpose of this study is to determine recommended Phase 2 dose [RP2D]) and the objective response rate of JNJ-42756493 (erdafitinib) in advanced hepatocellular carcinoma (HCC) participants with fibroblast growth factor (FGF) 19 amplification.
NCT02465060 ↗ Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting National Cancer Institute (NCI) Phase 2 2015-08-12 This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
NCT02699606 ↗ A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer O Active, not recruiting Janssen Research & Development, LLC Phase 2 2016-07-08 The primary purpose of this study is to evaluate objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of erdafitinib in a molecularly-defined subset of Asian participants with non-small-cell lung cancer (NSCLC), urothelial cancer, esophageal cancer and cholangiocarcinoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Erdafitinib

Condition Name

Condition Name for Erdafitinib
Intervention Trials
Recurrent Malignant Solid Neoplasm 3
Healthy 3
Neoplasm 3
Urinary Bladder Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Erdafitinib
Intervention Trials
Urinary Bladder Neoplasms 7
Neoplasms 6
Carcinoma 6
Lymphoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Erdafitinib

Trials by Country

Trials by Country for Erdafitinib
Location Trials
United States 261
Germany 11
Korea, Republic of 8
Taiwan 7
Belgium 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Erdafitinib
Location Trials
Texas 11
New York 10
Pennsylvania 9
North Carolina 9
Illinois 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Erdafitinib

Clinical Trial Phase

Clinical Trial Phase for Erdafitinib
Clinical Trial Phase Trials
Phase 3 1
Phase 2 14
Phase 1/Phase 2 2
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Erdafitinib
Clinical Trial Phase Trials
Recruiting 13
Not yet recruiting 5
Completed 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Erdafitinib

Sponsor Name

Sponsor Name for Erdafitinib
Sponsor Trials
Janssen Research & Development, LLC 12
National Cancer Institute (NCI) 7
Janssen Pharmaceutical K.K. 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Erdafitinib
Sponsor Trials
Industry 31
Other 8
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
AstraZeneca
Harvard Business School
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.